Webcast: Achieving Genome-Wide Success Part 2: Study Design in SNP and CNV Studies

Presenter: Dr. Christophe Lambert, Golden Helix CEO and Co-Chair of the FDA MAQC CNV Team

Date: October 7, 2009

Duration: 90 Minutes

ACCESS THIS WEBCAST:

Abstract

White Paper: Advanced Genotyping and Imputation

Learn how our state-of-the-art advanced genotyping and imputation solutions, using BEAGLE and BEAGLE CALL, can increase the power of your study,improve association results, and reduce the scope of followup fine-mapping efforts.

Download White Paper »

Study design can have an enormous impact on the validity and number of significant findings in genetic association studies.

In fact over 90% of the nearly three dozen genome-wide studies analyzed by Dr. Lambert and his team have evidence of poor study design, resulting in everything from uncorrectable data to spurious associations and false-positives.

In Part 2 of this educational webcast series as Dr. Lambert examines the effects poor study design can have on a project and strategies and techniques you can employ to avoid them in your own research.

Topic include:

• Impact of poor study design
• Minimizing sources of variability
• Advantages of population vs. family designs
• Pre-study power calculations
• Choice of genotyping platform
• Plating strategies
• Examples of good study design.

About the Presenter

Dr. Christophe Lambert is the President and CEO of Golden Helix, Inc., a bioinformatics company he founded in Bozeman, MT in 1998. Dr. Lambert graduated with his Bachelors in Computer Science from Montana State University in 1992 and received his Ph.D. in Computer Science from Duke University in 1997. Dr. Lambert is also currently the co-chair of the Food and Drug Administration’s Genome Wide Copy Number Variation Data Analysis Team of the Microarray Quality Control Consortium.